These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
498 related articles for article (PubMed ID: 31416571)
1. Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review. Cervena K; Vodicka P; Vymetalkova V Mutat Res Rev Mutat Res; 2019; 781():100-129. PubMed ID: 31416571 [TBL] [Abstract][Full Text] [Related]
2. Liquid biopsies: DNA methylation analyses in circulating cell-free DNA. Zeng H; He B; Yi C; Peng J J Genet Genomics; 2018 Apr; 45(4):185-192. PubMed ID: 29706556 [TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA in liquid biopsy: Current diagnostic limitation. Liu SC World J Gastroenterol; 2024 Apr; 30(15):2175-2178. PubMed ID: 38681986 [TBL] [Abstract][Full Text] [Related]
4. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review. Arzuaga-Mendez J; Prieto-Fernández E; Lopez-Lopez E; Martin-Guerrero I; García-Ruiz JC; García-Orad A Crit Rev Oncol Hematol; 2019 Jul; 139():7-15. PubMed ID: 31112884 [TBL] [Abstract][Full Text] [Related]
5. Diagnosis and monitoring of virus-associated cancer using cell-free DNA. Scholte LL; Bethony JM; Xian RR Curr Opin Virol; 2023 Jun; 60():101331. PubMed ID: 37187125 [TBL] [Abstract][Full Text] [Related]
6. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples. Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856 [TBL] [Abstract][Full Text] [Related]
7. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival. Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248 [TBL] [Abstract][Full Text] [Related]
8. Liquid Biopsy: Is There an Advantage to Analyzing Circulating Exosomal DNA Compared to cfDNA or Are They the Same? Kahlert C Cancer Res; 2019 May; 79(10):2462-2465. PubMed ID: 31043377 [TBL] [Abstract][Full Text] [Related]
9. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Luo H; Wei W; Ye Z; Zheng J; Xu RH Trends Mol Med; 2021 May; 27(5):482-500. PubMed ID: 33500194 [TBL] [Abstract][Full Text] [Related]
10. Cell-Free DNA: Applications in Different Diseases. Ranucci R Methods Mol Biol; 2019; 1909():3-12. PubMed ID: 30580419 [TBL] [Abstract][Full Text] [Related]
11. Predicting tumour content of liquid biopsies from cell-free DNA. Cardner M; Marass F; Gedvilaite E; Yang JL; Tsui DWY; Beerenwinkel N BMC Bioinformatics; 2023 Sep; 24(1):368. PubMed ID: 37777714 [TBL] [Abstract][Full Text] [Related]
12. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology. Ponti G; Manfredini M; Tomasi A Crit Rev Oncol Hematol; 2019 Sep; 141():36-42. PubMed ID: 31212145 [TBL] [Abstract][Full Text] [Related]
13. When Tissue Is the Issue: Expanding Cell-Free DNA "Liquid Biopsies" to Supernatants and Nonplasma Biofluids. Paulson V; Konnick EQ; Lockwood CH Clin Lab Med; 2022 Sep; 42(3):485-496. PubMed ID: 36150825 [TBL] [Abstract][Full Text] [Related]
14. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. Ai B; Liu H; Huang Y; Peng P Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821 [TBL] [Abstract][Full Text] [Related]
15. Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer. Shen N; Zhang D; Yin L; Qiu Y; Liu J; Yu W; Fu X; Zhu B; Xu X; Duan A; Chen Z; Wang X; Cao X; Zhao T; Zhou Z; Yu L; Qin H; Fang Z; Li JY; Liu Y; Xiong L; Yuan B; Li F; Zhang Y Oncol Rep; 2019 Aug; 42(2):549-560. PubMed ID: 31173267 [TBL] [Abstract][Full Text] [Related]
16. Chromatin- and nucleosome-associated features in liquid biopsy: implications for cancer biomarker discovery. Penny L; Main SC; De Michino SD; Bratman SV Biochem Cell Biol; 2024 Aug; 102(4):291-298. PubMed ID: 38478957 [TBL] [Abstract][Full Text] [Related]
17. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Song P; Wu LR; Yan YH; Zhang JX; Chu T; Kwong LN; Patel AA; Zhang DY Nat Biomed Eng; 2022 Mar; 6(3):232-245. PubMed ID: 35102279 [TBL] [Abstract][Full Text] [Related]
18. Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer. Gianni C; Palleschi M; Merloni F; Di Menna G; Sirico M; Sarti S; Virga A; Ulivi P; Cecconetto L; Mariotti M; De Giorgi U Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430675 [TBL] [Abstract][Full Text] [Related]
19. Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy. Zeng C; Stroup EK; Zhang Z; Chiu BC; Zhang W Cancer Commun (Lond); 2019 Mar; 39(1):12. PubMed ID: 30922396 [TBL] [Abstract][Full Text] [Related]
20. Circulating DNA and Liquid Biopsies in the Management of Patients with Cancer. Joosse SA; Pantel K Cancer Res; 2022 Jun; 82(12):2213-2215. PubMed ID: 35702889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]